Last weekend took place in London the 12th International Conference on Biosimilar Medicines, organized by the Biosimilars Division (EBG) of the European Generic Medicines Association (EGA) , which was attended by around 250 delegates from 34 countries, including various authorities, academics and researchers.
Adrian van den Hoven, CEO of EGA, invited delegates in his welcome address to propose ideas and solutions that could be adopted in the near future to close the information gap on biosimilars. In his words, "despite the fact that biosimilars have so far generated a great deal of clinical experience, achieving greater transparency of information regarding the biosimilar drugs continues to be one of the main challenges.”
In this way, the EGB requested during the conference that European regulators and European medical societies adopt an active role in informing the respective interest groups about the strict regulatory requirements to guarantee the safety, quality and efficacy of all Biological products that are approved for commercialization in Europe. In this sense, the congress also recalled the “contribution of biosimilars to the sustainability of national health systems".
On the other hand, van den Hoven, in statements to the newspaper El Global, stated that “there is a need for clear and impartial information from independent sources and in this the national authorities have a crucial role. Also, the pricing and reimbursement rules for biosimilars need to be different than for biosimilars. generic drugs"
